BioCentury
DATA GRAPHICS | Product Development

Phase I/II antibody levels support single shot for J&J COVID-19 vaccine: Data Byte

Immune responses lasted at least two months with one dose, and antibodies against the vaccine’s viral vector did not block response to a second dose 

January 15, 2021 2:48 AM UTC

Ahead of an imminent Phase III readout for a single shot of its COVID-19 vaccine, J&J’s updated Phase I/II data show neutralizing antibodies induced by a single dose last at least 10 weeks without decline.

Wednesday’s paper by Johnson & Johnson (NYSE:JNJ) in The New England Journal of Medicine also provides some reassurance that booster shots of JNJ-78436735 will be an option if needed. A second vaccination increased neutralizing antibody titers nearly threefold, despite the fact that the first vaccination induced antibodies against the vaccine’s adenovirus serotype 26 vector...

BCIQ Company Profiles

Johnson & Johnson